Antibody Catalogue

Working With CRT

Testimonials

Licensing Portfolio

Small Molecules

Biological Therapeutics

Mouse & Cell Line Portfolio

CRT's Discovery Pipeline

Commercialisation Routes

Antibody Portfolio - P

Antigen	Clone
p13 (SUC1)	AA10.2
p13 (SUC1)	AA22.2
p14 ARF	ARF 4C6/4
p21	AC8.3
p53	PAb 1103
p53	PAb 1104
p53	PAB 1802
p53	PAb 240
p53	PAb 1801
p53 (N terminal)	DO-1
p53 (N terminal)	DO-2
p53 (N terminal)	DO-7
p63	BU5
p63	BU7
p73	Polyclonal
p73 (alpha and beta specific)	Polyclonal
p75 Neurotrophin Receptor	p75 NTR (IC)
p75 Neurotrophin Receptor	p75 NTR (EC)
Pancreatic islet cells	LIV3D3
PCNA	5E6/2
PCTAIRE	G6.1
PE-CAM-1 (CD31)	JC70
Peroxidase (horseradish)	P6/38/20
PIP2	PIP2 2C11
Placental alkaline phosphatase (PLAP)	H17E2
Placental alkaline phosphatase (PLAP)	HD 11F7
Placental alkaline phosphatase (PLAP)	HD 8B6
Plasma cells	LIV3G11
Plasminogen	SBF1 C1.21
Platelet complex IIb/IIIa	189/21-10
Platelet-derived endothelial cell growth factor (PD-ECGF)	PGF 44C
Poliovirus type 1	Various
Poliovirus type 2	Various
Poliovirus type 3	Various
Polo-like kinase	AZ24
Polo-like kinase	AZ27
Polo-like kinase	AZ34
Polo-like kinase (mitotic form)	AZ44
Polyoma virus early antigens	PyC
Polyoma virus- Large T antigen	PyLT
Polyoma virus- middle T antigen	PyMT
POT1	MTA40
Progesterone-11	11P14
Proliferating cell marker	JC1
Proliferating cell nuclear antigen (PCNA)	PC10
Proliferating cell nuclear antigen (PCNA)	PC11
Proliferating cell nuclear antigen (PCNA)	PC5
Proliferating cell nuclear antigen (PCNA)	PC8
Prolyl Hydroxylase 1	PHD112/G7
Prolyl Hydroxylase 2	366G/76/3
Prolyl Hydroxylase 3	EG188e/d5
Protein kinase C	MC5
Proteasome complex; subunit 5a	AH1.1
pS157 HsCyk-4 Polyclonal	pS157 HsCyk-4
pS2	GE1
pS2	GE2
pY384-Tiam1 Polyclonal	pY384-Tiam1

For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com

Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information.